CG Oncology, Inc. (CGON)
(Delayed Data from NSDQ)
$25.29 USD
-1.65 (-6.12%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $25.27 -0.02 (-0.08%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CGON 25.29 -1.65(-6.12%)
Will CGON be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CGON based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGON
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
CGON: What are Zacks experts saying now?
Zacks Private Portfolio Services
Company News for May 14, 2025
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
Other News for CGON
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 19th Options Now Available For CG Oncology (CGON)
CGON's Price Target Lowered by RBC Capital, Rating Maintained | CGON Stock News
RBC Capital Adjusts Price Target for CG Oncology (CGON) Amid Positive Outlook | CGON Stock News